
|Videos|March 15, 2016
SGLT2 Inhibitors and Risk for Ketoacidosis and Urinary Tract Infections
Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.
Advertisement
Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Trump Executive Order Recommends Separating MMR Into 3 Shots
2
First-in-Class RNA Degrader Targets Historically ‘Undruggable’ MYC in Preclinical Multiple Myeloma Models
3
Suzetrigine-Based Multimodal Therapy Enables Opioid-Free Recovery in Patients Receiving Surgery
4
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
5




































































































